This morning, Merck (NYSE:MRK) reported fourth quarter earnings of $781 million, or 26 cents per share, as revenue slipped to $11.32 billion. Excluding one-time items, the company would have earned 88 cents per share, falling just short of Wall Street estimates. The company said it expects 2014 adjusted earnings in the range of $3.35 to $3.53 per share as Wall Street's consensus estimates falls within that range. The highlight from today's report was Merck's announcement that it had entered into a collaboration agreement with three other pharmaceutical companies to test the effects of Merck's new cancer drug when used in combination with theirs. Shares of Merck were higher on Wednesday morning, gaining 1.7% so far.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.